As part of the university's commitment to economic development and outreach, CTL hosts a variety of events to create connections between the Cornell campuses, industry members, entrepreneurs, and investors.
Mini Boot Camp: Leaving the Lab
April 30, 2014
4:00pm - 7:00pm
Location:Weill Cornell Medical Center, 1300 York Avenue, Room A-250, New York City
Open to: Weill Cornell and Cornell faculty, students, staff, alumni and the NYC community.
This Boot Camp focused on entrepreneurial activities outside the lab or university. Our panel talked about how they navigated their academic careers toward commercial endeavors.
A networking reception followed the panel where hors d'oeuvres and drinks were served.
To view photos from the event please click here.
Vice Provost for Technology Transfer, Cornell University
Alan is responsible for the strategic management of all technologies and intellectual property that arise from the research activities at Cornell University - both at the Weill Medical College in New York City and at the campus in Ithaca. Prior to joining Cornell Alan was Director and Assistant Vice Chancellor for Technology Transfer and Intellectual Property Services at the University of California, San Diego. From 1994 to 1998, he was Executive Director of the Iowa State University Research Foundation, Inc., and Director of Intellectual Property and Technology Transfer at Iowa State University. He holds a Ph.D. degree in Biological Sciences and an M.B.A. Alan is the inventor to eight US patents and has contributed 30 peer-reviewed research articles to scientific journals and six invited reviews and chapters to technical books.
Founder, Bialanx, Inc.
Matt Johnston works on enabling technology platforms for application to life sciences and healthcare fields. He currently leads Bialanx, an emerging bioelectronics company developing CMOS-based biochemical detection for a set of focused diagnostic applications. He also works as part of a small team designing high-speed electrophysiology amplifiers at Chimera Instruments. Matt was previously a co-founder of Helixis, a biological instrumentation spin-out from Caltech, which was acquired by Illumina in 2010. More recently, Matt performed technology and market assessment as an associate for a New York City venture capital firm investing in early-stage life sciences companies. Matt received a BS in Electrical Engineering from Caltech and MS and PhD degrees in Electrical Engineering from Columbia University. He was a graduate student and postdoc in the Bioelectronic Systems Lab at Columbia University with Prof. Ken Shepard.
Professor in Genetic Medicine, Weill Cornell Medical College, and Co-founder of Angiocrine Bioscience, Inc.
Shahin Rafii is a Professor in Genetic Medicine at Weill Cornell Medical College, a board certified hematologist-oncologist, and is engaged in basic and translational research as well as patient care. He is the director of the Ansary Stem Cell Institute at Weill-Cornell and is a Howard Hughes investigator. Shahin is also Co-founder of Angiocrine Bioscience, Inc. and is the principal inventor in numerous patents on therapeutic uses of vascular cells for stem cell self-renewal and organ regeneration as well as tumor targeting. He received his MD degree from Albert Einstein College of Medicine and carried out his post-doctoral training in vascular and hematopoietic stem cell biology at Weill-Cornell.
Associate Dean, Office of Therapeutics Alliances; Associate Director for Translational Research, NYU Cancer Institute and Founder of PTC Therapeutics and Co-founder of ImClone
Robert Schneider’s research is directed to the development, progression and metastasis of breast cancer, the interplay of the inflammatory response in human cancer and development of new clinical therapeutics and clinical trials based on this work. Robert is the Associate Dean for the new Office of Therapeutics and Industry Alliances, the Associate Director of Translational Cancer Research, and Co-Director of the Breast Cancer Research Program, at NYU School of Medicine. He is also a cofounding scientist of five biopharma companies, including PTC Therapeutics and ImClone Systems. Robert received his PhD from the Mount Sinai School of Medicine.